Drugs / combined acyl and desacyl ghrelin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02690987 | Aug 2015 → Aug 2019 | alcohol dependence, obesity disorder | Imperial College London | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01531283 | Feb 2011 → Apr 2013 | — | David Dalessio | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | combined acyl and desacyl ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01531283 ↗ |
| Known as | Desacyl ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02690987 ↗ |
| Route | Intravenous | “IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)” NCT01531283 ↗ |